Prostatic Specific Antigen and its Correlation with Prostatic Cancer in a Sample of Iraqi Population
Keywords:
Prostate specific antigen, Gleason scores, Prostate cancerAbstract
This study is directed at prostatic specific antigen (PSA) and its correlation with different Iraqi patients both normal and afflicted with prostatic cancer where numerous patients in Baghdad were screened for this tumor marker and their data collected after testing, this study included (51 ) persons diagnosed with prostatic cancer, collected from Baghdad medical city, and (22) patients as control for screening , both in different age groups (50-59,60-69,70- 79,80-89), results and correlations were calculated using IBM SPSS 20, through observing of the data collected and the comparison with normal standard levels, it is evident that an increase in PSA levels is strongly correlated with tumors of the prostate, also a correlation is apparent between the Gleason scores of prostate cancer patients and also their PSA levels.
Downloads
References
Karen Whalen, Richard Finkel, Thomas A.
Panavelil. Lippincott illustrated reviews:
Pharmacology. Sixth edition. 2014; Page 587.
Nicki R. Coiledge Stuart H. Ralston, Brian R.
Walker. Davidson's principles and practice of
medicine. 21st edition. 2010; Page 258.
Republic of Iraq Ministry of Health Iraqi
Cancer Board. Iraqi Cancer Registry. 2011;
Page 13-40.
Anand P, Kurmumakkara AB, Sundaram C,
Harikumar KB, Tharakan ST, Lai OS, Sung
B, Aggarwal BB. Cancer is a preventable
disease that requires major lifestyle changes.
Pharm Res. 2008; 25:2097-2116.
Bailar JC, Gornik HL. Cancer undefeated. N
Engl J Med. 1997;336:1569-1574
Lew E. and Garfinkel L.A. Mortality at ages
and older 755. 2007; 22:97-101.
T.H. van der Kwast, T. Wiegel, F. Zattoni. in
the cancer prevention study (CPSI). Cancer.
;40-210.
Heidenreich A., Bolla M., Joniau S., Mason
M.D., Matveev V., Mottet N., and Schmid HP. Guidelines on Prostate Cancer. European
Association of Urology. 2010;240-253.
Peyromaure M, Valeri A, Rebillard X,
Beuzeboc P, Richaud P, Soulie M, and
Salomon L . Characteristics of prostate cancer
in men less than 50-year-old. Prog. Urol.
;19,803-809.
Hsing A W, and Chokkalingam AP. Prostate
cancer epidemiology. Frontiers in Bioscience.
;l 1,1388-1413.
NaijisHadiAl-Saadi, AzizH. Jasim. Detectionof
New Marker in Prostate Cancer Patients with
Advanced Bone Metastasis. International
Journal of Cell Science and Biotechnology.
;2320—7574.
Roehrborn C.G., McConell J.D., Bonilla J.,
Rosenblatt S., Hudson P.B. and Malek G.H.
Serum prostate specific antigen is a strong
predictor of future prostate growth in men
with benign prostatic hyperplasia. PROSCAR
longterm efficacy and safety study. J Urol.
;163,13-20.
Greene K.L., Albertsen P.C. and Babaian R.J.
Prostate specific antigen best practice statement.
Update J Urol. 2009;182, 2232-2241.
Lovgren J, PiironenT, Overmo C. Production
of recombinant PSA and HK2 and analysis of
their immunologic cross¬
reactivity. BiochemBiophys Res
Commun.l995;213(3):888-95.
Hara M, Inorre T, Fukuyama T. Some
physicochemical characteristics of gammaseminoprotein, an antigenic component specific
for human seminal plasma. Jpn J Legal Med.
;25:322-324.
Li TS, Beling CG. Isolation and characterization of two specific antigens of
human seminal plasma. FertilSteril.
;24(2):134-44.
Sensabaugh GF. Isolation and characterization
of a semen-specific protein from human seminal
plasma: a potential new marker for semen
identification. J Forensic Sci. 1978; 23(l):106-
Graves HC, Sensabaugh GF, Blake ET.
Postcoital detection of a male-specific semen
protein. Application to the investigation of
rape. N Engl J Med. 1985;312(6):338-43.
Wang MC, Valenzuela LA, Murphy GP.
Purification of a human prostate specific
antigen. Invest Urol. 1979;17(2):159-63.
Papsidero LD, Wang MC, Valenzuela LA,
Murphy GP, Chu TM. A prostate antigen in
sera of prostatic cancer patients. Cancer Res.
;40(7):2428-32.
Stamey TA, Yang N, Hay AR. Prostate¬
specific antigen as a serum marker for
adenocarcinoma of the prostate. N Engl J
Med. 1987;317(15):909-16.
Chou R, Dana T, Bougatsos C, Fu R, Blazina I,
Gleitsmann K. Treatments for Localized Prostate
Cancer: Systematic Review to Update the 2002
U.S. Preventive Services Task Force
Recommendation. Rockville, MD: Agency for
Healthcare Research and Quality (US). 2011;12-
-EF-l.
Allan GM, Chetner MP, Donnelly BJ, Hagen
NA, Ross D, Ruether JD. Furthering the
prostate cancer screening debate (prostate
cancer specific mortality and associated risks).
Can Urol. Assoc. J. 2011;5(6):416-21.
Haythorn MR, Ablin RJ. Prostate-specific
antigen testing across the spectrum of
prostate cancer. Biomark Med.
;5(4):515-26.
Wolf AM, Wender RC, Etzioni RB,
Thompson IM, DAmico AV, Volk RJ.
American Cancer Society guideline for the
early detection of prostate cancer: update
CA Cancer J Clin. 2010;60(2):70-98.
Laux DL, Custis SE. Forensic Detection of
Semen III. Detection of PSA Using
Membrane Based Tests. Sensitivity Issues with
Regards to the Presence of PSAin Other Body
Fluids. Midwestern Association of Forensic
Scientists. 2008;05-ll.
Wimpissinger F, Stiffer K, Grin W, Stackl W.
The female prostate revisited: perineal
ultrasound and biochemical studies of female
ejaculate. The Journal of Sexual Medicine.
;4 (5): 1388-93.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
